Richard Lerner - Teva Pharmaceutical Independent Director
TEVA Stock | ILA 4,978 28.00 0.57% |
Director
Professor Dr. Richard Alan Lerner M.D. is an Independent Director of Teva Pharmaceutical Industries Ltd. Prof. Lerner served as President of The Scripps Research Institute from 1987 until January 2012. Prof. Lerner served as President of The Scripps Research Institute from 1987 until January 2012 and is currently a member of its Skaggs Institute for Chemical Biology where he is an Institute Professor and the Lita Annenberg Hazen Professor of Immunochemistry. Prof. Lerner served as a director of Kraft Foods Inc. from 2005 until 2012. He currently serves as a director of Opko Health Inc. Sequenom Inc. and IntraCellular Therapies Inc. Prof. Lerner was the recipient of numerous honors and prizes including the ParkeDavis Award in 1978 the San Marino Prize in 1990 and the Wolf Prize in Chemistry for 1995. Prof. Lerner was awarded the California Scientist of the Year Award in 1996 and the University of California Presidential Medal in 2002. Prof. Lerner is a member of the Royal Swedish Academy of Sciences and the United States National Academy of Sciences and holds honorary doctorates from esteemed academic institutions including the TechnionIsrael Institute of Technology and Oxford University. Prof. Lerner did undergraduate work at Northwestern University received B.M.S and M.D. degrees from Stanford University Medical School in 1964 and interned at Palo Alto Stanford Hospital from 1964 to 1965. With his long tenure as president of a major biomedical research organization and experience as a physician and a scientist Prof. Lerner provides valuable business scientific and management expertise. since 2012.
Age | 76 |
Tenure | 12 years |
Professional Marks | Ph.D |
Phone | (972) 3 914 8213 |
Web | www.tevapharm.com |
Teva Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 11 records | DIRECTOR Age | ||
Yair Aharonowitz | Compugen | 73 | |
Kinneret Savitsky | Compugen | 50 | |
JeanPierre Bizzari | Compugen | 64 | |
Joshua Shemer | Compugen | 63 | |
Gilead Halevy | Compugen | 51 | |
Ruth Arnon | Compugen | 86 | |
Sanford Zweifach | Compugen | 60 | |
Michal Preminger | Compugen | N/A | |
Eran Perry | Compugen | N/A | |
Dov Hershberg | Compugen | 74 | |
Arie Ovadia | Compugen | 67 |
Management Performance
Return On Equity | -0.24 | |||
Return On Asset | 0.0363 |
Teva Pharmaceutical Leadership Team
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Moshe Many, Independent Director | ||
Richard Daniell, Executive Vice President - European Commercial | ||
Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
Ronit SatchiFainaro, Independent Director | ||
Richard Lerner, Independent Director | ||
Galia Maor, Independent Director | ||
Janet Vergis, Independent Director | ||
Carlo Notaristefani, CEO of Global Operations and President of Global Operations | ||
JeanMichel Halfon, Statutory - independent director | ||
Eli Shani, Ex Portfolio | ||
Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations | ||
Abbas Hussain, Independent Director | ||
Yitzhak Peterburg, Director | ||
Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
Perry Nisen, Independent Director | ||
Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director | ||
David Stark, Executive Vice President, Chief Legal Officer | ||
Amir Elstein, Vice Chairman of the Board | ||
Dan Suesskind, Director | ||
Arie Belldegrun, Independent Director | ||
Richard Egosi, Chief Legal Officer and Group Executive VP | ||
Andrew Weil, Chief Accounting Officer | ||
Jean Halfon, Statutory - independent director | ||
Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio | ||
Robert Koremans, President CEO-Global Specialty Medicines | ||
Gerald Lieberman, Independent Director | ||
Roberto Mignone, Independent Director | ||
Rosemary Crane, Independent Director | ||
Nechemia Peres, Independent Director | ||
Roger Abravanel, Independent Director | ||
Eyal Desheh, CFO and Group Executive VP | ||
Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
Kare Schultz, CEO Pres | ||
Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication | ||
Amir Weiss, VP Officer | ||
Brendan OGrady, Executive Vice President - North America Commercial | ||
Michael Hayden, President - Global Research and Development, Chief Scientific Officer | ||
Gabrielle Sulzberger, Statutory Independent Director | ||
Eric Drape, Executive Vice President - Global Operations | ||
Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee | ||
Eliyahu Kalif, Chief Financial Officer, Executive Vice President, Director | ||
Kathleen Veit, Global VP | ||
Joseph Nitzani, Independent Director | ||
Deborah Griffin, Chief Accounting Officer | ||
Timothy Wright, Head - Business Development, Strategy and Innovation | ||
Sigurdur Olafsson, President and CEO - Global Generic Medicines Group | ||
Murray Goldberg, Independent Director | ||
Dan Propper, Independent Director | ||
Ory Slonim, Independent Director | ||
Michael McClellan, Chief Financial Officer, Executive Vice President | ||
Kevin Mannix, Vice President Head of Investor Relations | ||
Kaare Schultz, President, Chief Executive Officer, Director | ||
Sol Barer, Independent Chairman of the Board | ||
Eli Kalif, Chief Financial Officer, Executive Vice President, Director |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.24 | |||
Return On Asset | 0.0363 | |||
Profit Margin | (0.16) % | |||
Operating Margin | 0.18 % | |||
Current Valuation | 102.13 B | |||
Shares Outstanding | 1.11 B | |||
Shares Owned By Insiders | 0.77 % | |||
Shares Owned By Institutions | 5.30 % | |||
Price To Book | 1.18 X | |||
Price To Sales | 2.32 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Teva Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Teva Pharmaceutical's short interest history, or implied volatility extrapolated from Teva Pharmaceutical options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Teva Stock analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |